Oxaloacetate for Health & Longevity

Evidence Review created on 09/24/2026 using AI4L / Opus 5.5

Also known as: Oxaloacetic Acid, Oxalacetic Acid, OAA, 2-Oxobutanedioic Acid, Oxosuccinic Acid, Ketosuccinic Acid, Anhydrous Enol-Oxaloacetate, AEO, benaGene, Jubilance, CRONaxal

Motivation

Oxaloacetate (oxaloacetic acid) is a small molecule that every cell makes as part of its main energy cycle, the chain of reactions inside the cell’s power plants that turns food into usable energy. Sold as a heat-stabilized dietary supplement, it attracts longevity-minded adults because it appears to push cells toward the energy state produced by eating less, without the hunger.

Interest began with a laboratory finding that the compound lengthened the lives of tiny worms. Since then, human research has shifted away from aging itself toward fatigue after viral illness and brain energy use in dementia. A government-funded mouse program also tested it for lifespan, and nearly all human studies trace back to the company that makes the main product.

This review examines what the animal and human evidence shows about the benefits and risks of oxaloacetate for health-focused adults, how far that evidence reaches beyond the patient groups studied so far, and how the supplement is dosed, monitored and sourced.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Oxaloacetic acid

A chemistry-first encyclopedia entry covering structure, instability, Krebs cycle (the mitochondrial energy loop) roles and nitrogen metabolism, with a brief summary of the roundworm lifespan data.

Examine

Oxaloacetate benefits, dosage, and side effects

A brief supplement page describing oxaloacetate’s Krebs-cycle role and its link to ketone production; the research breakdown is archived and the research feed is limited to subscribers.

ConsumerLab

No dedicated ConsumerLab article or product review on oxaloacetate exists; oxaloacetate appears only as short passages inside broader ConsumerLab articles on recovering from COVID-19 and on supplements for energy and fatigue.

Systematic Reviews

This section lists the only systematic review on PubMed that evaluates oxaloacetate.

Dietary Supplementation for Fatigue Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)-A Systematic Review - Dorczok et al., 2025

Of 14 supplement studies, one tested oxaloacetate: the open-label (unblinded) pilot, which reduced fatigue; high bias risk across studies prevents firm conclusions.

No systematic review or meta-analysis addresses oxaloacetate’s principal risks (gastrointestinal effects, neurological worsening) or its lifespan claims; the risk side of the trade-off is unrepresented.

Mechanism of Action

Oxaloacetate is a four-carbon intermediate of the Krebs cycle, where it joins acetyl-CoA (the two-carbon fuel unit released from sugar and fat) to start each turn. Three routes are proposed:

Redox shift: cytoplasmic malate dehydrogenase (MDH, the enzyme turning oxaloacetate into malate) consumes NADH and regenerates NAD+ (the reduced and oxidized forms of a coenzyme whose ratio signals cellular fuel status), mimicking calorie restriction and activating AMPK and FOXO (Williams et al., 2009).
Mitochondrial signaling: in mice, oxaloacetate raised PGC-1α (a master switch for building mitochondria) and lowered NF-κB (a master switch for inflammatory genes) activity in brain (Wilkins et al., 2014).
Glutamate scavenging: glutamate-oxaloacetate transaminase (GOT, identical to the liver-panel enzyme aspartate aminotransferase, AST) uses oxaloacetate to convert blood glutamate (the main excitatory brain messenger) into aspartate, drawing excess glutamate out of injured brain (a 2012 narrative review by Campos et al.).

The competing view: oral doses of 1–2 g/day did not reliably raise plasma oxaloacetate in a trial using Terra Biological-supplied product (Vidoni et al., 2021), and excess intracellular oxaloacetate damaged mitochondria in worm and cell models (Zhang et al., 2026).

Pharmacology: no receptor selectivity; human half-life unmeasured; distribution to brain shown in mice, with cellular entry via dicarboxylate transporters (membrane carriers for two-acid molecules); metabolism by MDH, GOT, citrate synthase (the enzyme joining it to acetyl-CoA) and spontaneous breakdown to pyruvate (the end product of sugar breakdown), not by cytochrome P450 (CYP, liver drug-metabolizing) enzymes.

Historical Context & Evolution

Oxaloacetate was identified in the 1930s as a core Krebs cycle intermediate, a biochemical fact rather than a therapy. A 1968 Japanese study identified it as the active component of a blood-sugar-lowering plant remedy and reported lower blood sugar in 16 of 21 people with diabetes and in diabetic animals (Yoshikawa, 1968), an uncontrolled early lead.

Interest in health optimization came from calorie-restriction research. Alan Cash, a physicist-entrepreneur, reasoned that raising the NAD+/NADH ratio might mimic eating less; a 2009 worm study he co-authored reported longer lifespan through the dietary-restriction pathway (Williams et al., 2009). His company, Terra Biological, developed a heat-stabilized form, since plain oxaloacetate breaks down within hours in solution.

The mouse test that followed was negative: the National Institute on Aging’s Interventions Testing Program (ITP, a three-site mouse lifespan program) found no lifespan effect (Strong et al., 2013). Critics read this as refuting the longevity claim; supporters argue that the single dose tested and possible breakdown of the compound in food may explain the null result.

Research then pivoted to the brain: glutamate scavenging for stroke and glioma (a primary brain tumor), and University of Kansas trials in Alzheimer’s (Vidoni et al., 2021) and Parkinson’s disease, with Terra Biological as collaborator (NCT01741701). In 2017 the US Food and Drug Administration (FDA) issued a warning letter over brain-tumor claims for a medical-food version (FDA warning letter). Since 2020 the focus has shifted to fatigue in ME/CFS and long COVID, where manufacturer-funded randomized trials now exist.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no oxaloacetate outcome has been replicated on a human clinical endpoint in more than one randomized trial, and the two randomized fatigue trials disagree on their primary endpoints.

Medium 🟩 🟩

Reduced Emotional Premenstrual Symptoms

In a placebo-controlled crossover randomized trial (each woman took both treatments in turn) of 48 women with premenstrual syndrome (PMS, mood and physical symptoms before menstruation), two capsules daily of oxaloacetate 100 mg plus vitamin C 150 mg improved validated depression, anxiety, stress and aggression scores over one cycle (Tully et al., 2020). The rice-flour placebo lacked vitamin C, the manufacturer sponsored and co-authored the trial, and it has not been replicated. Glutamate lowering is the proposed mechanism.

Magnitude: Mean score improvements of 54.1% for depression, 51.4% for anxiety, 35.8% for perceived stress and 17.8% for aggression during the active cycle.

Low 🟩

Reduced Fatigue in ME/CFS and Long COVID ⚠️ Conflicted

Manufacturer-funded open-label (Cash & Kaufman, 2022) and 3-month ME/CFS randomized (Cash et al., 2024) trials reported less fatigue; the maker’s 6-week long COVID randomized trial missed its primary endpoint (Vernon et al., 2025), perhaps from shorter treatment or a different illness. The net reading is a modest, inconsistent benefit.

Magnitude: 40.5% versus 20% of participants achieved at least 25% fatigue reduction over 3 months, while the end-of-study difference in mean Chalder Fatigue Questionnaire (an 11-item validated fatigue scale) score did not reach significance.

Improved Cognitive Performance After Viral Illness ⚠️ Conflicted

Computerized reaction-time scores improved more on oxaloacetate in long COVID (Vernon et al., 2025); in ME/CFS the gain reached significance only at day 60, while controls had non-significantly more cognitive-only responders at day 90 (Vernon et al., 2025). Both are manufacturer-funded secondary outcomes. The net reading is an unconfirmed signal.

Magnitude: Total cognitive efficiency rose 10.7% on 2 g/day versus no change on control after 6 weeks in long COVID; in ME/CFS the between-group difference reached significance only at day 60 of 90.

Blood Glucose Regulation

A 1968 uncontrolled Japanese series gave sodium oxaloacetate to 21 people with diabetes and reported blood-sugar lowering in 16 (Yoshikawa, 1968); mouse work showed activated brain insulin signaling (Wilkins et al., 2014). Modern data are thin: glucose screening in the Alzheimer’s trial showed no consistent change (Vidoni et al., 2021).

Magnitude: 16 of 21 people with diabetes (76%) showed lower blood sugar in the uncontrolled 1968 series; no controlled trial has measured a glucose outcome.

Speculative 🟨

Lifespan Extension ⚠️ Conflicted

Oxaloacetate extended roundworm lifespan (Williams et al., 2009), but lifelong feeding did not extend lifespan in genetically diverse mice (Strong et al., 2013). No human data exist. The net reading is unproven in mammals.

Brain Mitochondrial Growth and Neurogenesis

Injected oxaloacetate increased brain mitochondria-building signals and neurogenesis (formation of new neurons) while lowering inflammation in mice (Wilkins et al., 2014). The basis is animal work only.

Increased Brain Glucose Uptake in Alzheimer’s Disease

In Alzheimer’s disease, 2 g/day for one month raised FDG-PET (a brain glucose-use scan) signal versus 1 g/day (Vidoni et al., 2021). The basis is an imaging biomarker without placebo; cognition did not improve.

Acute Brain Injury Neuroprotection via Glutamate Scavenging ⭕️ Not Central to Health & Longevity

Oxaloacetate reduced nerve-cell loss after induced stroke (Knapp et al., 2015) and traumatic brain injury (Zlotnik et al., 2012) in rats. The basis is animal only; it bears on acute brain-injury treatment.

Motor Neuron Protection in Animal Models ⭕️ Not Central to Health & Longevity

Injected oxaloacetate preserved strength and delayed paralysis in mice modeling amyotrophic lateral sclerosis (ALS, a fatal motor-neuron disease), without extending lifespan (Tungtur et al., 2021). The basis is animal only; it bears on ALS treatment.

Slower Glioma Growth ⭕️ Not Central to Health & Longevity

Oral oxaloacetate slowed implanted glioma (a primary brain tumor) growth and prolonged survival in rodents (Ruban et al., 2012). The basis is animal only; it bears on brain-cancer treatment.

Liver Protection

Oxaloacetate reduced chemically induced liver injury in mice by lowering oxidative stress and supporting energy production (Kuang et al., 2018). The basis is animal and cell work only.

Antiviral Immune Defense

Cells sense oxaloacetate to strengthen interferon (antiviral signal) responses; supplementation gave broad antiviral protection, while oxaloacetate-deficient mice were more susceptible to lethal influenza (Jin et al., 2025). The basis is animal and cell work only.

Kidney Protection in Diabetes

Injected oxaloacetate reduced kidney-tubule damage, scarring and immune-cell infiltration in diabetic mice by restoring mitochondrial balance (Zhang et al., 2026). The basis is animal and cell work only.

Benefit-Modifying Factors

Genetic polymorphisms: No pharmacogenetic variants are known. Rare inborn errors of the malate-aspartate shuttle (the system moving fuel electrons into mitochondria), such as deficiency of MDH2 (mitochondrial malate dehydrogenase) or GOT2 (mitochondrial glutamate-oxaloacetate transaminase), alter oxaloacetate handling; common variants are unstudied.
Baseline biomarkers: Plasma oxaloacetate is reported low in ME/CFS (Cash et al., 2024); in the randomized ME/CFS trial, higher baseline fatigue and longer illness were associated with stronger response in an exploratory model (Cash et al., 2024). No marker predicts benefit in healthy adults.
Sex: About 80% of fatigue-trial participants were women and the premenstrual trial enrolled only women; sex did not predict response in the ME/CFS trial (Cash et al., 2024).
Pre-existing conditions: Every human benefit signal comes from disease populations (ME/CFS, long COVID, Alzheimer’s disease, premenstrual syndrome); healthy adults may have less energy-metabolism deficit to correct.
Age: Alzheimer’s participants, mostly in their 70s, showed brain-metabolism changes without cognitive gain (Vidoni et al., 2021); mice started at 4 months showed no lifespan gain (Strong et al., 2013), and no trial targets healthy older adults.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Gastrointestinal Upset

Nausea, dyspepsia (indigestion), stomach upset and abdominal pain are the most consistently reported adverse events. In the 3-month ME/CFS trial at 2 g/day, 3 of 42 reported nausea and one withdrew for severe nausea with abdominal pain (Cash et al., 2024); in Alzheimer’s disease, taking doses with food relieved nausea (Vidoni et al., 2021). Most cases are mild, one severe case led to withdrawal, and in the ME/CFS trial controls reported similar complaints.

Magnitude: About 7% nausea at 2 g/day over 3 months; up to 12.5% gastrointestinal complaints at 2 g/day over one month; 4 of 18 versus 0 of 15 in a Parkinson’s pilot run with Terra Biological as collaborator (NCT01741701).

Medium 🟥 🟥

No risk reaches Medium: the remaining adverse events rest on uncontrolled series, statistically untested counts in one small pilot, or controlled trials in which controls reported similar rates.

Low 🟥

Insomnia and Stimulant-Like Jitteriness

Insomnia occurred in 1 of 26 ME/CFS patients on 1 g/day (Cash & Kaufman, 2022) and, described as jitteriness, in 3 of 18 versus 1 of 15 on placebo in a Parkinson’s pilot (NCT01741701). Data are sparse and small.

Magnitude: About 4% in the open-label fatigue trial and 17% versus 7% in the Parkinson’s pilot, with neither difference statistically tested.

Headache

Headache was among the most common possibly related events at 2 g/day in the ME/CFS trial (Cash et al., 2024) and appeared in the open-label long COVID arms (Cash & Kaufman, 2022). Controls reported similar events, so causation is uncertain.

Magnitude: 3 of 42 participants (about 7%) over 3 months at 2 g/day, a rate not separated from the control group.

Worsening of Parkinson’s Symptoms ⚠️ Conflicted

In a 4-month pilot of 100 mg daily, 7 of 18 on oxaloacetate versus 1 of 15 on placebo reported worsening, yet rating-scale scores did not differ (NCT01741701). In Alzheimer’s disease, 2 g/day did not worsen cognition (Vidoni et al., 2021). The net reading is an unreplicated signal.

Magnitude: 39% versus 7% reported disease worsening and 5 versus 1 withdrew for adverse events, although motor rating scores did not differ.

Speculative 🟨

Low Blood Sugar

A 1968 report of blood-sugar lowering in diabetes (Yoshikawa, 1968) implies hypoglycemia (low blood sugar) risk with diabetes drugs, but the Alzheimer’s trial saw no glucose change (Vidoni et al., 2021). The basis is theoretical.

Impaired Muscle Endurance

In mice, oxaloacetate uncoupled muscle mitochondria via JNK (a stress-signaling enzyme) and UCP2 (a protein letting mitochondria burn fuel without making energy), causing fatigue (Yin et al., 2024). The basis is animal only.

Mitochondrial Membrane Damage

Genetically driven oxaloacetate build-up disrupted mitochondrial inner-membrane folds through MIC60 (a membrane-shaping protein) in worms and cells (Zhang et al., 2026). The basis is mechanistic only.

Theoretical Support of Tumor Growth ⚠️ Conflicted

Oxaloacetate is the direct precursor of aspartate, a nutrient limiting some tumors’ growth (Sullivan et al., 2018), yet it slowed gliomas in rodents. The basis is mechanistic; the net reading is unresolved.

Risk-Modifying Factors

Genetic polymorphisms: No variants are known to alter tolerance. People with inborn errors of Krebs-cycle or malate-aspartate shuttle enzymes (MDH2, GOT2, or pyruvate carboxylase, the enzyme making oxaloacetate from pyruvate) may accumulate oxaloacetate and are untested.
Baseline biomarkers: Low fasting glucose or recurrent hypoglycemia (low blood sugar) raises theoretical concern because of claimed glucose-lowering; abnormal liver enzymes complicate interpretation, since the transaminase uses oxaloacetate.
Sex: No sex-specific adverse-event differences are reported; trials were mostly female, so male tolerance data are thinner. Pregnancy and breastfeeding are unstudied.
Pre-existing conditions: Parkinson’s disease carries the only worsening signal; active cancer raises the theoretical aspartate concern; functional gut disorders, common in ME/CFS, may amplify gastrointestinal upset.
Age: Older Alzheimer’s participants tolerated 2 g/day for one month (Vidoni et al., 2021); longer exposure in adults over 75 and in people taking many medications is unstudied.

Key Interactions & Contraindications

Glucose-lowering drugs (metformin, glipizide, insulin): Caution; theoretical additive glucose lowering could cause hypoglycemia. Mitigation: fasting-glucose checks during the first 2–4 weeks, with prescriber-led dose review.
Parkinson’s medications (carbidopa-levodopa, pramipexole): Caution; a pilot trial reported more disease worsening on oxaloacetate (NCT01741701). Mitigation: weekly symptom tracking and stopping if motor function declines.
Glutamate-modulating drugs (memantine, riluzole): Monitor; theoretical additive glutamate lowering with unknown clinical consequence. Mitigation: introducing one agent at a time.
Chemotherapy (temozolomide): Caution; possible altered tumor response, since oxaloacetate feeds aspartate synthesis; a rodent glioma study showed longer survival with the pair (Ruban et al., 2012), but human data are absent. Mitigation: co-administration confined to a supervised oncology protocol.
Over-the-counter stimulants (caffeine, pseudoephedrine): Caution; additive insomnia and jitteriness. Mitigation: no late-day co-dosing.
Over-the-counter anti-inflammatories (ibuprofen, naproxen): Monitor; additive stomach irritation. Mitigation: taking both with food.
Supplements with additive glucose lowering (berberine, chromium, alpha-lipoic acid): Caution; additive hypoglycemia risk. Mitigation: fasting-glucose checks when combining.
Supplements sharing the redox or Krebs-cycle target (nicotinamide riboside, nicotinamide mononucleotide, alpha-ketoglutarate, malate): Monitor; overlapping NAD+ and Krebs-cycle effects with untested additive consequences. Mitigation: adding one at a time.
Prolonged fasting or ketogenic diet (very-low-carbohydrate, high-fat eating): Monitor; combined with oxaloacetate in rodent glioma work (Augur et al., 2018), with additive glucose lowering. Mitigation: glucose and hydration checks.

Populations who should avoid Oxaloacetate:

Pregnancy (any trimester) and breastfeeding, owing to absent safety data
Children and adolescents under 18, as no trial enrolled minors
Active malignancy outside a supervised oncology trial
Parkinson’s disease on dopaminergic therapy (dopamine-replacing drugs; any Hoehn and Yahr stage, a 1–5 Parkinson’s severity scale), given the worsening signal
Inborn errors of Krebs-cycle or malate-aspartate shuttle metabolism (MDH2, GOT2 or pyruvate carboxylase deficiency)
Recurrent hypoglycemia or insulin-treated diabetes with HbA1c (3-month average blood sugar) below 6.5%, without glucose monitoring

Risk Mitigation Strategies

Low start, slow titration: Protocols begin at 100 mg daily and, for higher-dose use, rise by 500 mg every 1–2 weeks toward 1 g twice daily, limiting nausea and jitteriness.
Dosing with meals: Taking doses with a full meal relieved nausea in trials (Vidoni et al., 2021), reducing gastrointestinal upset.
Morning and midday timing: A last dose before about 2 p.m. reduces the risk of insomnia and stimulant-like jitteriness.
Glucose checks: Weekly fasting glucose for 4 weeks, or a continuous glucose monitor, alongside glucose-lowering drugs guards against unrecognized hypoglycemia.
Neurological symptom log: In Parkinson’s disease, weekly motor and cognitive ratings, with stopping if worsening persists beyond 2 weeks, address the worsening signal.
Cancer screening status: Up-to-date, age-appropriate cancer screening before long-term use addresses the theoretical tumor-growth concern.

Therapeutic Protocol

Low-dose longevity regimen: 100 mg once or twice daily of heat-stabilized oxaloacetate with vitamin C, the benaGene regimen promoted by Alan Cash of Terra Biological; no human lifespan or aging-marker trial supports this dose.
High-dose fatigue regimen: 1 g twice daily (2 g/day) for 6–12 weeks, used in the Bateman Horne Center (Cash et al., 2024) and David Kaufman (Cash & Kaufman, 2022) trials in ME/CFS and long COVID.
Neurology research regimen: 500 mg to 1 g twice daily, tested by Russell Swerdlow’s University of Kansas group (Vidoni et al., 2021); an ALS dose-finding trial with Terra Biological as collaborator (NCT04204889) escalated to 2.5 g twice daily.
Competing approaches: Dietary restriction, fasting and ketogenic eating target the same NAD+ and energy-sensing pathways without a supplement; neither approach has been compared head-to-head.
Time of day: Morning and early afternoon, with meals, given reports of insomnia and nausea.
Half-life: Human half-life is unmeasured; oral doses barely shift plasma levels (Vidoni et al., 2021), and the compound is rapidly metabolized or converted to pyruvate.
Single versus split dosing: High-dose trials split doses twice or three times daily, while the 100 mg Parkinson’s pilot (NCT01741701) used once-daily dosing; split dosing is standard for 1 g or more.
Genetic polymorphisms: No pharmacogenetic dose guidance exists; APOE4 (the main genetic Alzheimer’s risk variant) carriers have not been analyzed separately.
Sex: No sex-specific dosing; women dominate trial data, so the same regimens apply to men by extrapolation.
Age: Older adults with Alzheimer’s disease tolerated 2 g/day for one month (Vidoni et al., 2021); no age-specific dose adjustment has been studied.
Baseline biomarkers: People with fasting glucose already near 70–80 mg/dL may notice glucose-lowering effects sooner; no biomarker guides dose.
Pre-existing conditions: ME/CFS and long COVID use the high-dose regimen; in Parkinson’s disease, the only placebo-controlled pilot reported more worsening, and no regimen has been tested for this group.

Discontinuation & Cycling

Duration: Evidence covers at most 4 months; any lifelong use for longevity is an extrapolation without long-term safety data.
Withdrawal effects: None reported; no trial followed participants after stopping, so whether fatigue benefits persist or fade is unknown.
Tapering: No taper is required at 100 mg; at 2 g/day, stepping down over 1–2 weeks allows fatigue changes to be noticed.
Cycling: No evidence supports cycling; some users take 8–12 week courses with breaks to judge individual response.

Sourcing and Quality

Stabilized form: Plain oxaloacetic acid breaks down within hours in solution; products rely on anhydrous enol-oxaloacetate (AEO, a heat-stabilized form) packaged dry with vitamin C.
Brands: Terra Biological supplies nearly all human-grade product (benaGene, Jubilance and a 500 mg high-dose capsule); reagent-grade laboratory powder lacks stability and purity assurance.
Third-party testing: No independent product testing by ConsumerLab or similar programs exists; a certificate of analysis showing at least 95% oxaloacetate content, the stability threshold used in the Alzheimer’s trial (Vidoni et al., 2021), is the available quality check.
Storage: Sealed, cool, dry storage slows breakdown; heat and moisture accelerate conversion to pyruvate.
Name confusion: Oxaloacetate is not oxalate (the kidney-stone mineral); labels listing “oxalic acid” are a different compound.

Practical Considerations

Time to effect: Fatigue changes appeared within 2–6 weeks in trials; any glucose or aging effects lack a human timeline.
Common pitfalls: Buying unstabilized powder, expecting the 100 mg dose to match 2 g trial effects, and treating worm lifespan data as human evidence.
Regulatory status: Sold in the US as a dietary supplement; the FDA issued a 2017 warning letter over brain-tumor claims, and the manufacturer reports orphan-drug designations for glioma, ALS and liver cancer.
Cost and payer bias: High-dose use costs far more than low-dose capsules; no insurer covers oxaloacetate, so no institutional payer incentive for or against it is apparent.
Conflict of interest: Nearly every human trial was funded, co-authored or supplied by Terra Biological or its affiliate MetVital, both led by Alan Cash.

Interaction with Foundational Habits

Sleep: Blunting (possible). Insomnia and jitteriness were reported in small trials, plausibly from increased energy-metabolism activity; an early-afternoon last dose and sleep tracking during the first 2 weeks address this.
Nutrition: Potentiating (theoretical). Oxaloacetate is promoted as a calorie-restriction mimic; combining it with time-restricted eating (eating within a daily window of about 8 hours) or ketogenic diets overlaps the same NAD+ pathway. Dosing with food limits nausea; no nutrient depletion is known.
Exercise: Uncertain, possibly blunting. Mouse data (Yin et al., 2024) show muscle fatigue and reduced performance with raised oxaloacetate, while a human ME/CFS trial showed modestly improved upright activity (Vernon et al., 2025); dosing immediately before hard training remains untested.
Stress management: Indirect. The premenstrual trial (Tully et al., 2020) showed lower perceived stress and anxiety scores, possibly through glutamate lowering; no cortisol data exist.

Monitoring Protocol & Defining Success

Baseline testing before starting establishes reference values: fasting glucose, HbA1c and fasting insulin to detect glucose-lowering effects; a liver panel with ALT (alanine aminotransferase, a liver-cell enzyme that leaks into blood when liver cells are injured) and AST, since AST is the enzyme that metabolizes oxaloacetate; and kidney function by eGFR (estimated glomerular filtration rate, a kidney filtration estimate). Fatigue-focused users also record a baseline Chalder Fatigue Questionnaire score.

Ongoing monitoring follows this cadence: fasting glucose weekly for the first 4 weeks when combined with glucose-lowering drugs; repeat of the full panel and fatigue score at 6–12 weeks; then every 6–12 months with continued use. Success for fatigue means at least a 25% score reduction by 12 weeks; for longevity use, no validated success marker exists, so stable or improved glucose and liver markers without side effects is the practical benchmark.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Fasting glucose	75–90 mg/dL	Detect glucose lowering	Conventional range 70–99 mg/dL; 8–12 hour fast; morning draw
HbA1c	4.8–5.4%	Longer-term glucose trend	Conventional normal below 5.7%; reflects about 3 months; pair with fasting glucose
Fasting insulin	2–6 µIU/mL	Insulin sensitivity	Conventional range up to about 25 µIU/mL; fasting morning draw
ALT	10–25 U/L	Liver safety	Conventional upper limit about 40–56 U/L, lab-dependent; avoid hard exercise 48 hours before
AST	10–25 U/L	Liver safety; oxaloacetate-handling enzyme	Conventional upper limit about 40 U/L; exercise raises it transiently
eGFR	Above 90 mL/min/1.73 m²	Kidney clearance	Conventional normal above 60; hydrate normally; pair with creatinine
Plasma oxaloacetate	No established target; track change from own baseline	Absorption check	Research assay only; unstable sample, high background levels
Chalder Fatigue Questionnaire	No established target; track at least 25% reduction from own baseline	Fatigue response	Validated 11-item scale; same time of day each assessment

Qualitative markers:

Daytime energy and post-exertional recovery
Mental clarity and concentration
Sleep onset and continuity
Digestive comfort after doses
Mood and premenstrual symptom severity, where relevant
For Parkinson’s disease, motor steadiness and tremor

Emerging Research

ALS dose-finding trial: NCT04204889, a phase 1 University of Kansas trial, with Terra Biological as collaborator, in 18 participants escalating from 500 mg to 2.5 g twice daily, with dose-limiting toxicity as primary endpoint; completed 2023, results unpublished, and would define the upper safe dose.
Cognitive complaints after breast cancer: NCT04290897, a phase 2 University of California, Los Angeles Jonsson Comprehensive Cancer Center trial, with the manufacturer’s affiliate MetVital as collaborator, in 18 survivors, primary endpoint FACT-Cog (a validated self-rated cognition scale) perceived impairment; completed 2024, unpublished.
Glioblastoma add-on to chemotherapy: NCT04450160, a phase 2 glioblastoma (the most aggressive glioma) MetVital-sponsored trial planning 80 patients with overall survival as primary endpoint; status unknown, and the sponsor is led by the product’s inventor.
Post-radiation brain metabolism: NCT05720624, a planned Mayo Clinic phase 1 study of oxaloacetate after brain radiotherapy, was withdrawn before enrolling, leaving brain-penetration questions open.
Independent fatigue replication: All randomized fatigue data are manufacturer-funded (Vernon et al., 2025); an independent trial with a pre-specified between-group endpoint could confirm or overturn the benefit.
Mammalian lifespan retest: The mouse lifespan test was null (Strong et al., 2013); a retest with the stabilized form and verified dosing would settle whether the worm result translates.
Antiviral immune sensing: Cells sense oxaloacetate through cytoplasmic malate dehydrogenase to boost interferon (the body’s front-line antiviral signal) responses, and supplementation protected mice against influenza (Jin et al., 2025), a possible mechanism for post-viral benefits.
Mitochondrial harm from excess: Oxaloacetate build-up damaged mitochondrial membranes in worm and cell models (Zhang et al., 2026); dose-response studies must show whether supplement doses stay below harmful intracellular levels.
Muscle fatigue in mice: Raised oxaloacetate impaired exercise performance in mice (Yin et al., 2024), a finding that human exercise studies could confirm or refute.

Conclusion

Oxaloacetate is a natural energy-cycle molecule sold as a heat-stabilized supplement and promoted as a way to mimic the effects of eating less. For health-focused adults, its appeal rests on a plausible idea and early laboratory results rather than on human evidence of slower aging.

The strongest human findings are modest and come from patients, not healthy people: fewer mood symptoms before menstruation in one small trial, mixed results for fatigue after viral illness, and signs of changed brain energy use in dementia without better thinking. The founding worm lifespan result did not carry over to mice. Animal work on brain protection, brain tumors and the liver remains unconfirmed in people, and lower blood sugar in diabetes rests on one old, uncontrolled report.

Short-term use appears well tolerated, with mild stomach upset as the main complaint. Less settled concerns include poor sleep, a small signal of worsening in Parkinson’s disease, and laboratory hints that excess amounts can strain muscle and cell energy systems. Long-term safety beyond a few months is unknown.

The evidence base carries a clear conflict of interest: the company that makes the main product, and its drug-development affiliate, funded or co-authored nearly every human study. Independent academic work exists mainly in dementia research and animal studies. Overall, the evidence is thin, short and largely company-linked, and the case for use as a longevity measure in healthy adults remains uncertain.

Top - Benefits - Risks - Protocol

Oxaloacetate for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Medium 🟩 🟩

Reduced Emotional Premenstrual Symptoms

Low 🟩

Reduced Fatigue in ME/CFS and Long COVID ⚠️ Conflicted

Improved Cognitive Performance After Viral Illness ⚠️ Conflicted

Blood Glucose Regulation

Speculative 🟨

Lifespan Extension ⚠️ Conflicted

Brain Mitochondrial Growth and Neurogenesis

Increased Brain Glucose Uptake in Alzheimer’s Disease

Acute Brain Injury Neuroprotection via Glutamate Scavenging ⭕️ Not Central to Health & Longevity

Motor Neuron Protection in Animal Models ⭕️ Not Central to Health & Longevity

Slower Glioma Growth ⭕️ Not Central to Health & Longevity

Liver Protection

Antiviral Immune Defense

Kidney Protection in Diabetes

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Gastrointestinal Upset

Medium 🟥 🟥

Low 🟥

Insomnia and Stimulant-Like Jitteriness

Headache

Worsening of Parkinson’s Symptoms ⚠️ Conflicted

Speculative 🟨

Low Blood Sugar

Impaired Muscle Endurance

Mitochondrial Membrane Damage

Theoretical Support of Tumor Growth ⚠️ Conflicted

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion